Guidelines for Complications of Cancer Treatment Vol VIII Part B

More documents

Recommendations

Info

Section — IGeneralContributorsDr. V Parmar, MS, DNBDr. M Nadkarni, MS, DNBDr. N Nair, DNBDr. A Kulkarni, MDDr. V Patil, MDDr. J Divatia, MDDr. V Agarwal, MD FRCADr. Sajid Qureshi, MS DNBDr. M Agarwal, D Ortho, MS Ortho, DNB OrthoDr. A Puri, MS ortho
Page 1 and 2: Guidelines forComplications ofCance
Page 3: Dedicated toAll our patients atThe
Page 6 and 7: Section IIHead & Neck 151Complicati
Page 8 and 9: PrefaceTreatment of cancer by vario
Page 12 and 13: Complications In BreastCancer Surge
Page 14 and 15: prophylaxis has been studied in mul
Page 16 and 17: seroma [19,20]. Use of electrocaute
Page 18 and 19: oader excision laterally to allow a
Page 20 and 21: References:1. Prophylaxis against w
Page 22 and 23: smoking is predictive for post-mast
Page 24 and 25: 5. Long-acting versus short-acting
Page 26 and 27: undergoing gastrointestinal operati
Page 28 and 29: 10. Does re-operation predispose to
Page 30 and 31: peripheral lymph-like fluid but con
Page 32 and 33: dissection for breast cancer had ei
Page 34 and 35: feasible and safe on an outpatient
Page 36 and 37: (early) or day 7 (delayed). All pat
Page 38 and 39: with either scalpel (n = 38) or ele
Page 40 and 41: formation) were recorded. RESULTS:
Page 42 and 43: esulting in a seroma. Currently acc
Page 44 and 45: 27. Pain and other symptoms after d
Page 46 and 47: The study was a randomized, double-
Page 48 and 49: and exercise, have been shown to be
Page 50 and 51: Surgical Site InfectionsSSIIncision
Page 52 and 53: 1. Purulent drainage from a drain t
Page 54 and 55: Category 1B: Do not routinely use v
Page 56 and 57: Anaesthesia and PerioperativeManage
Page 58 and 59: Design: Randomized controlled trial
Page 60 and 61:
hospitalization was prolonged by 2.
Page 62 and 63:
Blood Component Therapy:Red cells:R
Page 64 and 65:
Intervention: None.Outcome: Hospita
Page 66 and 67:
Inadequate: The available studies c
Page 68 and 69:
Multimodal Techniques for Pain Mana
Page 70 and 71:
Extensive and proactive evaluation
Page 72:
3. Difficult tracheal intubation: (
Page 75 and 76:
8. Equipment suitable for emergency
Page 77 and 78:
2. An evaluation for general clinic
Page 79 and 80:
educed anesthetic doses in the pres
Page 81 and 82:
anaesthesia reduced the risk of awa
Page 83 and 84:
Surviving Sepsis Campaign:Internati
Page 85 and 86:
Table 1. Determination of the quali
Page 87 and 88:
ooCulture other sites as clinically
Page 89 and 90:
o Epinepphrine, phenylephrine and v
Page 91 and 92:
oDo not use antithrombin therapy (1
Page 93 and 94:
ooUse either intermittent bolus sed
Page 95 and 96:
Consideration for limitation of sup
Page 97 and 98:
contraindicated (1B); avoiding rout
Page 99 and 100:
comparisons). During the same perio
Page 101 and 102:
had similar baseline characteristic
Page 103 and 104:
participating intensive-care units
Page 105 and 106:
Sprung CL, Annane D, Keh D, et al f
Page 107 and 108:
increased mechanical constraints pl
Page 109 and 110:
Megaprosthesis is the most attracti
Page 111 and 112:
complications are usually more rela
Page 113 and 114:
Springfield D (Eds), Surgery for bo
Page 115 and 116:
Infection in Limb Salvage Surgery :
Page 117 and 118:
considered to be two-stage revision
Page 119 and 120:
In contrast, articulating spacers p
Page 121 and 122:
The new endoprosthesis then was ins
Page 123 and 124:
Diagnosis of InfectionThe diagnosis
Page 125 and 126:
FDG-PET scanning had a positive pre
Page 127 and 128:
10. Lord CF, Gebhardt MC, Tomford W
Page 129 and 130:
31. Holzer G, Windhager R, Kotz R:
Page 131 and 132:
Antibiotic Prophylaxis in Orthopaed
Page 133 and 134:
124be wasteful, but potentially haz
Page 135 and 136:
are less active than cefazolin agai
Page 137 and 138:
3. There is no evidence to support
Page 139 and 140:
ate from 2.7% to 1.3%, with a nonsi
Page 141 and 142:
9. Saline irrigation of the wound c
Page 143 and 144:
gentamicin-resistant organisms occu
Page 145 and 146:
treatment of Staphylococcus aureus
Page 147 and 148:
24. Nelson CL, Green RA, Porter RA,
Page 149 and 150:
orthopedic wound infections. Acta O
Page 151 and 152:
62. Masari BA, Duncan CP, Beauchamp
Page 153 and 154:
involvement. several factors limit
Page 155 and 156:
involvement in four of the 20 patie
Page 157 and 158:
these were large and deep-seated so
Page 160:
Section — IIHead and NeckContribu
Page 163 and 164:
ManagementPrinciples The most impor
Page 165 and 166:
4. Baker S.R. and Swanson N.A. Reco
Page 167 and 168:
Osteoradionecrosis of the MandibleD
Page 169 and 170:
Injury or dental extractions: Any s
Page 171 and 172:
the patients responded to HBO alone
Page 173 and 174:
9. Lyons A, Ghazali N. Osteoradione
Page 175 and 176:
XerostomiaXerostomia is present in
Page 177 and 178:
eduction in salivary pH, decreased
Page 179 and 180:
170to those that received placebo.
Page 181 and 182:
has been on techniques like IMRT, I
Page 183 and 184:
8. Eisbruch A, Kim HM, Terrell JE,
Page 185 and 186:
tonsillar region Int J Radiat Oncol
Page 187 and 188:
Deterioration in the Quality of lif
Page 189 and 190:
Toxicity gradingGrade 0 Grade 1 Gra
Page 191 and 192:
Shown to decrease the severity and
Page 193 and 194:
Problems Associated with Free Tissu
Page 195 and 196:
- A flap with arterial blockade sho
Page 197 and 198:
- Graft loss is commonly due to she
Page 199 and 200:
References1. Microvascular free fla
Page 201 and 202:
Recurrent Laryngeal Nerve (RLN)a. R
Page 203 and 204:
When the EBSLN is damaged unilatera
Page 205 and 206:
References1. Hermann M, Alk G, Roka
Page 207 and 208:
Hypocalcemia FollowingThyroidectomy
Page 209 and 210:
Prevention Thorough knowledge of th
Page 211 and 212:
Annual Ophthalmologist evaluation f
Page 213 and 214:
Risk factors Poor nutritional statu
Page 215 and 216:
However, more often than not, inser
Page 217 and 218:
Post-Laryngectomy TracheostomalSten
Page 219 and 220:
Previous tracheostomy - no conclusi
Page 221 and 222:
ChondroradionecrosisIntroduction an
Page 223 and 224:
Concomitant chemotherapy may compou
Page 225 and 226:
despite repeated negative biopsies
Page 227 and 228:
Swallowing Dysfunction after Treatm
Page 229 and 230:
Commonest dysfunction on MBS after
Page 231 and 232:
Head rotated to the Improves vocal
Page 233 and 234:
Hypothyroidism After Treatment forH
Page 235 and 236:
References1) Long-term incidence of
Page 237 and 238:
IV - Moderately severe dysfunction
Page 239 and 240:
The functional status of the facial
Page 241 and 242:
Frey’s SyndromeFrey’s syndrome
Page 243 and 244:
The affected area is painted with i
Page 245 and 246:
ReferencesManagement of Frey syndro
Page 247 and 248:
Incidence:Depends upon the type of
Page 249 and 250:
References1. Impact of shoulder com
Page 251 and 252:
After every neck dissection, put th
Page 253 and 254:
Algorithm for management of fistula
Page 255 and 256:
PreventionThe main principle to pre
Page 257 and 258:
difficult to appreciate. Characteri
Page 259 and 260:
Operative Techniques include:1) End
Page 261 and 262:
ooCisplatin, as single agent is the
Page 263 and 264:
oooin many trials though the differ
Page 265 and 266:
creatinine in males, 0.85 X (140-ag
Page 267 and 268:
o Treatment of febrile neutropenia
Page 269 and 270:
6. Seiwert TY, Salama JK and Vokes
Page 272 and 273:
Complications of Abdomino-PelvicRad
Page 274 and 275:
With these doses, the rate of necro
Page 276 and 277:
sigmoid colon and rectum being in c
Page 278 and 279:
complication rate of late rectal to
Page 280 and 281:
after radiation therapy, bladder ir
Page 282 and 283:
partial symptomatic resolution (P =
Page 284 and 285:
increased with concurrent administr
Page 286 and 287:
Suggested Reading:1. Hall EJ. Radio
Page 288 and 289:
Radiation Induced Second MalignantN
Page 290:
Table I: Risk of subsequent cancer
Page 293 and 294:
traversed by a charged particle but
Page 295 and 296:
modality treatment than RT alone (6
Page 297 and 298:
vulva, anal canal and oropharynx) a
Page 299 and 300:
Registries, 1973-2000. National Can
Page 301 and 302:
Suggested Reading:1. Goldsby R, Bur
Page 303 and 304:
adiation dose, and age at treatment
Page 305 and 306:
dose. The excess relative risk for
Page 307 and 308:
Radiation Induced Cardiac &Pulmonar
Page 309 and 310:
Acute fibrinous pericarditis can pr
Page 311 and 312:
Cardiac Morbidity & MortalityCardio
Page 313 and 314:
effusion a mean of 150 days after t
Page 315 and 316:
3. Mittal S, Berko B, Bavaria J, et
Page 317 and 318:
Carver JR, Shapiro CL, Ng A, Jacobs
Page 319 and 320:
RESULTS: In the total group, the ri
Page 321 and 322:
For women diagnosed during 1993-200
Page 323 and 324:
5.4%, SE 1.3, 2p=0.0002; overall mo
Page 325 and 326:
PneumonitisThe clinical syndrome of
Page 327 and 328:
Measurable end points of Pulmonary
Page 329 and 330:
Useful radiation therapy planning p
Page 331 and 332:
7. Rubin, P. Radiation toxicity: Qu
Page 333 and 334:
profibrotic cytokines and molecules
Page 335 and 336:
Graham MV, Purdy JA, Emami B, Harms
Page 337 and 338:
Radiation MyelopathyIntroduction:Sp
Page 339 and 340:
probably secondary to damage to the
Page 341 and 342:
Time Course of Events: The onset ma
Page 343 and 344:
since previous treatment, although
Page 345 and 346:
tried 36 . Novel therapies as stem
Page 347 and 348:
14. Abramson N, Cavanaugh PJ. Short
Page 349 and 350:
MRI in differentiating spinal cord
Page 351 and 352:
acceptability of the types of treat
Page 353 and 354:
Radiation Induced Central NervousSy
Page 355 and 356:
sensory or motor impairment. Numero
Page 357 and 358:
Randomized trial in craniospinal ra
Page 359 and 360:
RT to brain has been implicated as
Page 361 and 362:
that there will be higher probabili
Page 363 and 364:
Pseudo-progression needs to be diff
Page 365 and 366:
CONCLUSION: The results document a
Page 367 and 368:
Intelligence Score Chart (WISC), wh
Page 369 and 370:
hypothesized ordering of groups in
Page 371 and 372:
PATIENTS AND METHODS: Follow-up stu
Page 373 and 374:
had undergone surgical procedure in
Page 375 and 376:
which mirrors the increased inciden
Page 377 and 378:
with population incidence rates thr
Page 380:
Section — IVMedical OncologyContr
Page 383 and 384:
Initial investigations - Complete b
Page 385 and 386:
In low risk group, patient may rece
Page 387 and 388:
trial design issues.1 Fluconazole s
Page 389 and 390:
Duration of treatment may depend up
Page 391 and 392:
Antibacterial agents-Overall risk E
Page 393 and 394:
Gram positive DOSE Spectrum Comment
Page 395 and 396:
Broad spectrum DOSE Spectrum Commen
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
6. Bow EJ, Rotstein C, Noskin GA, e
Page 403 and 404:
2. Delayed CINV: Nausea and vomitin
Page 405 and 406:
Recommended Treatment OptionsAcute
Page 407 and 408:
Evidence Based Management Guideline
Page 409 and 410:
Management of refractory and breakt
Page 411 and 412:
serotonin antagonist and dexamethas
Page 413 and 414:
(no vomiting and no use of rescue t
Page 415 and 416:
within 24 hours after the start of
Page 417 and 418:
with age, often becoming clinically
Page 419 and 420:
guidelines for screening & manageme
Page 421 and 422:
Level Treatment Method of Frequency
Page 423 and 424:
15. Wallace WH, Blacklay A, Eiser C
Page 425 and 426:
health status domains were assessed
Page 427 and 428:
of childhood cancer survivors is no
Page 429 and 430:
Tumor Lysis SyndromeDefinition: Tum
Page 431 and 432:
the grade of CTLS is defined by the
Page 433 and 434:
Alkalinization for patients who wil
Page 435 and 436:
deficiency should include a thoroug
Page 437 and 438:
icarbonate and calcium should not b
Page 439 and 440:
and should have ready access to ras
Page 441 and 442:
Table 3 Risk Factors for Tumor Lysi
Page 443 and 444:
Table 5 Recommended Rasburicase Dos
Page 445 and 446:
1. Guidelines for the management of
Page 447 and 448:
3. A randomized comparison between
Page 449 and 450:
acid levels (6.4-16.8 mg/dl; median
Page 451 and 452:
adiographic pattern is the hilar ly
Page 453 and 454:
study involving 105 patients was 8.
Page 455 and 456:
10. Sostman HD, Matthay RA, Putman
Page 457 and 458:
distinguish between a normal GFR an
Page 459 and 460:
of methotrexate induced nephropathy
Page 461 and 462:
Bibliography1. De Jonge MJ, Verweij
Page 463 and 464:
Mucositis and GastrointestinalToxic
Page 465 and 466:
pathogenesis is similar for gastroi
Page 467 and 468:
acceptable oral protocol include re
Page 469 and 470:
Treatment of gastrointestinal mucos
Page 471 and 472:
Hepatotoxicity ofChemotherapeutic A
Page 473 and 474:
Capecitabine is the prodrug for 5-F
Page 475 and 476:
Topotecan causes elevation of trans
Page 477 and 478:
Daunorubicin: Reduce dose by 25% if
Page 479 and 480:
9. Spriggs DR, Stopa E, Mayer RJ, e
Page 481 and 482:
Dermatologic Toxicity of Antineopla
Page 483 and 484:
ecause 15% of scalp hairs are not i
Page 485 and 486:
5. Batchelor D. Hair and cancer che
Page 487 and 488:
Anemia and Cancer - incidence, etio
Page 489 and 490:
most accurate method for detecting
Page 491 and 492:
levels, to define anemia and this m
Page 493 and 494:
Darbopoietin Vs Epoetin Alfa: Is Th
Page 495 and 496:
arm (2.4 g/dl) compared to patients
Page 497 and 498:
12. Yellen SB, Cella DF, Webster K,
Page 499 and 500:
490NOTES
Page 501:
NOTES
show all

Guidelines for Complications of Cancer Treatment Vol VIII Part B

Create successful ePaper yourself

Delete template?

Save as template?